<p>Relapse remains the primary cause of treatment failure and death in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Novel therapeutic approaches are imperative for those who are refractory to blinatumomab and chimeric antigen receptor T (CAR-T) cell therapy. CAR-natural killer (NK) cells have emerged as promising candidates for novel cancer immunotherapies, with enhanced antitumor activity and low rates of adverse events.…
Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T
Journal for ImmunoTherapy of Cancer | | Wang, N., Liu, L., Zhang, L., Li, J., Wan, Y., Li, X., Chen, X., Yin, Z., Zhang, A., Zhang, X., Chen, Y., Hu, T., Zhang, Y., Liu, F., Zhu, X., Yang, W.
Topics: blood-cancer, immunotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer